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Background: The appropriate use of medicines continues to be an important area of inter-disciplinary research
activity both in the UK and beyond. Key qualitative work in this area in the last decade has included the ‘medicines
resistance’ model of medicine-taking, which was based on a meta-ethnography of 37 qualitative studies. This model
proposed that patients approach medicine-taking as ‘passive accepters’, ‘active accepters’, ‘active modifiers’ or
‘complete rejecters’, of which the latter two categories were considered to show ‘resistance’ to medicines. However,
critical assessment of the model appears to be currently lacking, particularly in terms of its use in clinical practice.
This paper seeks to contribute to the literature in this area by critically examining the practical application of the
model in light of the findings from a qualitative, follow-up study of cardiac rehabilitation patients’ perspectives and
experiences of using medicines.
Methods: Following ethical approval, in-depth, audiotaped, qualitative interviews were conducted with fifteen
patients who had completed a UK hospital-based cardiac rehabilitation programme. Participants were aged 42–65,
white British and from a variety of socioeconomic backgrounds. Interview topics included perspectives on coronary
heart disease, medicine-taking and lifestyle changes. Follow-up interviews with ten patients approximately nine
months later explored whether their perspectives had changed.
Results: The findings suggest that the active/passive and accepter/modifier distinctions may not allow for clear
determination of which profile a patient fits into at any given point, and that definitions such as ‘accepter’ and
‘resistance’ may be insufficiently discerning to categorise patients’ use of medicines in practice. These problems
appear to arise when the issue of patients’ accounts about medicines adherence are considered, since patients may
have concerns or disquiet about medicines whether or not they are adherent and the model does not consider
disquiet in isolation from adherence.
Conclusions: Practical application of the ‘medicines resistance’ model of medicine-taking may be problematic in
this patient group. Dissociation of disquiet about medicines from medicines adherence may allow for a focus on
helping patients to resolve their disquiet, if possible, without this necessarily having to be viewed in terms of its
potential effect on adherence.* Correspondence: s.j.white@keele.ac.uk
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Lay peoples’ use of the medicines they are prescribed (or
purchase) remains an area of study that continues to
generate a huge empirical literature. Numerous studies
have demonstrated that people find following medication
regimens problematic, that various lifestyle, psychological
and social factors are implicated in this, that inappropri-
ate medication use adversely impacts on patients’ health
outcomes and hospital admissions, and the costs of this
to health care systems are highly significant [1]. Various
interventions and policies have been proposed to address
this, but few simple and effective solutions have been
identified [2]. However, in the previous twenty years
there has been an increasing emphasis in the empirical
and policy field on firstly challenging the terms and as-
sumptions underpinning what has been referred to as
‘compliance’ research and secondly, exploring how rela-
tionships between prescriber and medicines user might
be re-configured to ensure appropriate use of medicines
[3,4]. For example, there have been calls to move away
from what has been regarded as the rather rigid and pro-
fessionally focused term compliance to embrace adher-
ence and the notion of concordance has emerged as a
way of illustrating the importance of understanding the
users’ perspectives in relation to medication practices
[3,5]. Despite this, the basic problem of how people
orientate themselves to their medicines and their medica-
tion regimens remains.
To understand this area in more depth, researchers
have increasingly been drawn to qualitative approaches
and one of the most interesting papers to have emerged
in this field in recent years is that by Pound et al [6].
Their ‘medicines-resistance’ model of medicine-taking
(Figure 1) was developed from a meta-ethnography [7]Passive 
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Figure 1 Pound et al’s ‘medicines resistance’ model of medicine-takinof 37 qualitative research studies published between 1992
and 2001 that primarily explored lay peoples’ views of
medicine-taking. Their model placed peoples’ approaches
to prescribed medicines into the four categories of ‘pas-
sive accepter’ (accepts medicines without question), ‘active
accepter’ (accepts medicines after self-evaluation), ‘active
modifier’ (modifies their medicines regimen after self-
evaluation) and ‘complete rejecter’ (rejects taking medi-
cines completely). Of these categories, the latter two were
considered to show what they described as ‘medicines-
resistance’. The ‘medicines-resistance’ model differed from
Dowell and Hudson’s model of medicine-taking in that it
included the category of ‘active accepter’ of medicines [8].
This is an important distinction because although Dowell
and Hudson found that most patients evaluated medicines
for themselves before accepting them, their model only
categorised such acceptance as a passive process [8]. In
contrast, the ‘medicines-resistance’ model recognised this
as an active process, as is modification of the medication
regimen after a process of self-evaluation.
This paper aims to critically examine the practical appli-
cation of the ‘medicines resistance’ model of medicine-
taking in light of the findings of a qualitative, follow-up
study of cardiac rehabilitation (CR) patients’ perspectives
and experiences with medicines-taking. Critical assessment
of the model appears to be currently lacking and CR pa-
tients are a contrasting patient group from those included
in Pound et al’s meta-ethnography [6]. CR is a multidiscip-
linary coronary heart disease (CHD) secondary prevention
strategy principally involving structured exercise, psycho-
social support and information provision (on various topics
including medicines) that has been shown to have health
benefits for patients who have had a cardiac event (e.g.
myocardial infarction) or surgical intervention [9]. StudiesThese groups show resistance
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with the ‘medicines-resistance’ model and no clear picture
is apparent in the available research on this point; some
studies report that CR patients appear to be adherent with
medicines, at least up to six months after CR programme
attendance [10], whereas other studies suggest that adher-
ence declines in the first three years, although perhaps
less or more slowly compared to patients who did not at-
tend CR [11]. With these issues in mind, the discussion
now turns to the approach and the methods used in the
present study.
Methods
A qualitative approach to the study was taken on the
grounds of being better suited to exploring the range,
depth and complexity of people’s perspectives than a
quantitative approach [12]. In-depth interviews were
used because this technique enables individual participants’
perspectives to be explored in detail [13]. Lincolnshire
NHS Research Ethics Committee approval for the study
was obtained.
A purposive sample of patients were recruited from a
UK district general hospital-based CR programme, which
ran for six weeks on a one session per week basis. The
programme involved multidisciplinary input from health
professionals such as nurses, physiotherapists, occupational
therapists, dietitians, pharmacists and social workers. This
included assessment of individual physical, psychological
and social needs. It also involved provision of structured
exercise sessions and information on various topics includ-
ing lifestyle modification recommendations (e.g. smoking
cessation and adopting a healthy diet and exercise regime),
stress management, local CHD patient groups, and the
use, benefit and harms of medicines [14]. Each session in-
cluded group-based information provision on one of these
topics for approximately 45 minutes, followed by struc-
tured exercises and relaxation.
All patients who attended the CR programme were
considered eligible to participate, provided that written
consent was given. The first author attended the CR
programme to explain the study to patients and distribute
Information Sheets. On successive weeks the first author
repeated this process, but also waited at the end to give pa-
tients an opportunity to volunteer. Written consent and a
contact telephone number were obtained. Each patient was
then contacted to arrange an interview location of their
choice and a mutually convenient time. The initial inter-
views were conducted after patients had finished at-
tending the CR programme, which was approximately
three months after hospital discharge. Fifteen patients were
interviewed. This number was determined by the point of
apparent saturation of the data [15].
The interview guide used was based on a review of the
literature. The topics included patients’ perspectives onCHD and the CR programme, and their perspectives on
lifestyle modification and medicine-taking. Open, non-
leading questions about these topics were asked. These
questions were intended only to serve as prompts for
the topics of interest; other questions were often asked
that were not specifically in the guide or were asked in a
slightly different way to the guide. This was so that pa-
tients could talk about their experiences and perspec-
tives as they wished and express themselves in their own
words with minimal prompting. Questions were asked at
points that flowed from what patients said, generally to
clarify or explore the responses given, rather than stick-
ing rigidly to the order in the guide. This ensured that
the topics of interest were covered, but allowed issues of
importance to interviewees to emerge. The first author
conducted the interviews and made detailed field notes
after each interview of significant events and non-verbal
cues to aid interpretation of the data. The interviews
were audiotaped and transcribed verbatim.
Re-recruitment of the patients for follow-up interviews
started approximately nine months after the initial inter-
view. Hospital records were checked to determine whether
any of the patients had died. Fourteen patients were subse-
quently contacted in writing to invite them to participate,
of which ten were recruited. The same interview topics
were used, although the focus was on whether patients’
views had changed since the initial interview. All interviews
were audiotaped and transcribed verbatim.
Data analysis began by reading and repeated re-
reading of the transcripts to identify similarities. Drawing
on the principles of grounded theory, concepts embodied
in these similarities were grouped into themes and
scrutinised to identify the properties or characteristics of
each theme [15]. Further interview transcripts were com-
pared with the themes identified to examine the similar-
ities and differences in detail [15]. Themes were modified
accordingly so that the properties of each were more
clearly defined or refined [15,16]. Themes were compared
with each other and relationships between them identified
and examined in detail in order to develop an overall struc-
ture [15,16]. Care was taken to account for views or experi-
ences that differed from the majority view, which resulted
in the properties of themes being further refined and a
clearer interpretation of the data [13,16]. The first author
kept a journal of reflections and thoughts about each inter-
view and interpretations of the data, which included
diagrams of possible relationships between emerging cat-
egories to guide or reflect the analysis [13]. The themes
were further refined through discussion between the au-
thors. A considerable amount of time was spent thinking
about the relationships between concepts in the data, the
properties of themes and variations in the data. This in
turn prompted further scrutiny of the transcripts and fur-
ther examination of the themes to ensure that the analysis
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ued throughout the study up to and including the stages of
writing up, as further insights were gained [16].
Results
Eleven of the participants were men and four were
women. All were White British within the age range
of 42–65 and from a variety of socioeconomic back-
grounds. Thirteen were married and living with a partner,
whilst two patients lived alone. All of the patients had
attended the CR programme because they had had a
heart attack (the term heart attack is used here in prefer-
ence to myocardial infarction because this was the term
that patients used). Patients’ descriptions of their other
medical conditions were used, as specific medical diagno-
ses were not usually known. Details of patients’ medi-
cines were compiled from patients’ memory and, where
available, the medicines themselves, repeat prescriptions
and patients’ own medication lists. These usually in-
cluded aspirin, a statin, a beta-blocker, an ACE inhibitor,
and glyceryl trinitrate spray. Seven patients were taking
alternatives to these medicines or additional medicines
for chest pain (e.g. nitrates).
All of the patients were keen to report that they were
taking their medicines as prescribed, although we recog-
nise that it cannot be said that this was definitely so,
given that these were self-reports. Having said this,
patients demonstrated that they were taking their medi-
cines in one or more of four ways: by specifically pointing
out that they were prepared to take them; by talking
about having a strategy to remember to take them;
by showing that where doses had not been taken as
usual, this had not been intentional; and by tolerating
or seeking medical advice about side effects, rather than
deciding not to continue taking the medicines thought to
be responsible.
As such, none of the patients were clearly ‘rejecters’ or
‘active modifiers’ of their medicines as described in the
medicines resistance model, so the discussion now con-
siders whether their acceptance of medicines aligns with
the ‘medicines-resistance’ model, starting with ‘passive
acceptors’. We draw on the medicines resistance typ-
ology to guide our analysis.
‘Passive acceptance’ of medicines?
In the initial interviews, six patients appeared to accept
their medicines or at least did not express any particular
concerns about taking them, and neither did they talk
about wanting more information about their medicines
than they had been given. There were no obvious differ-
ences between their medicines and those of the rest of
the patients (e.g. they were not taking fewer medicines
than the others). The situation was much the same in
the follow-up series of interviews, as five of the originalsix patients still did not express any worries or concerns
about taking their medicines (the sixth patient did not
participate in the follow-up interviews). However, the ex-
tent to which this could be considered a passive process
was open to question, since patients appeared to have
undertaken some form of evaluation and, in the absence
of any problems that concerned them, appeared to have
accepted the need to take their medicines. This was ex-
emplified by one patient who said:
“I couldn’t tell you what this one actually does and
what that one does, although at the time I read what
this one did and what that one did…I’ve a good idea
that as long as you’re feeling alright they’re doing
whatever it is they’re supposed to do and do you really
need to know what they’re doing?” (R10: male)
Another patient pointed out about his medicines that
the doctor had not “given them to me for nothing” and
‘so I’ll put them down my neck as long as they say I’ve
got to do it’. As a further example, a patient talked about
being given a booklet about her medicines and so knew
that ‘this one’s for your heart, that one’s for diabetes and
that’. Subsequently, she pointed out that:
“…quite obviously what I’ve been prescribed is
supposed to be helping me, so therefore it’s up to
me to keep taking them isn’t it; keep taking the
tablets.” (R3: female)
On the other hand, there also appeared to be a strong
sense that these patients felt they ought to trust and
accept their doctors’ prescribing decisions and instruc-
tions, in other words, in line with a Parsonian view of
the doctor – patient relationship. Within this group of
patients, there was a clear desire to present themselves
as following the doctors’ instructions and demonstrate
‘compliance’. For example, one patient pointed out that
“if he [doctor] tells me I’ve got to take [medicines] that’s
all I need to know, not what specific purpose it’s doing”.
As far as he was concerned “the people who should
know about that are the doctors, they should know the
milligrams and things like that”.
Nevertheless, applying the passive/active acceptance
distinction in the ‘medicines-resistance’ model to these
patients seemed problematic, as their self-evaluation of
medicines suggested an almost continuously active process
of evaluation and monitoring, but in other respects their
approach could be seen as being passive in that they
reporting taking their medicines as prescribed. However,
the other patients expressed more significant concerns
about taking medicines, and the discussion now focuses on
whether their approach to these concerns aligns with the
medicines resistance model.
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In the initial interviews, nine patients (i.e. over half) spon-
taneously expressed worries and concerns about taking
medicines and we have grouped these into four areas: side
effects; how long they would need to take the medicines
for; differences in information from written sources of in-
formation compared to that provided by health profes-
sionals; and, why doses of certain medicines frequently
changed. The issues in applying the ‘medicines-resistance’
model here concerned the extent to which patients could
be considered to have accepted their medicines in the ab-
sence of resolution of their concerns (i.e. whether they
did accept them), and more significantly that some patients
sought medical advice because of difficulty in tolerating
side effects (i.e. whether they modified their regimen). The
following examples illustrate these points.
Three patients raised concerns as a result of experien-
cing side effects. Of these, one patient in particular said
that he had had “problems with tablets”. He had subse-
quently taken a keen interest in the potential side effects
of his medicines and said the information he had been
given had not given enough indication of the likelihood
of getting any of the side effects listed. This had been
compounded by the sheer number of potential side ef-
fects. The underlying significance was that the informa-
tion had not helped him determine whether or not the
“discomfort” he had been experiencing in his chest was
a side effect of the alternative medicine (losartan) he
had been prescribed when an initial choice had given
him a dry tickly cough, whereas he had been able to
“quickly pick up on” this cough being a side effect of
the initial choice (ramipril). He had sought medical ad-
vice because he was unable to tolerate the cough. The
situation became more confusing when he was later
told (by another patient) that the alternative “doesn’t
work as well” as the initial choice because this made
him wonder whether this was why he was getting “dis-
comfort”, rather than it being a side effect. Neverthe-
less, he pointed out that he was continuing to take his
medicines as prescribed.
The second patient talked about wanting to know
the likelihood of getting side effects from her medi-
cines because she too had been having difficulty in
tolerating the dry tickly cough induced by the same
initial choice of medicine (ramipril), and after seeking
medical advice was due to start taking an alternative. Her
concern seemed to be that she might also experience side
effects from the alternative choice. The third patient said
that she found that when she took one of her medicines
(atenolol) it made her “feel a bit queer sometimes” and de-
scribed experiencing symptoms suggestive of postural
hypotension. This seemed to have been what had caused
her to take more interest in the atenolol than her other
medicines but she said that the information she had beengiven had not helped her to understand why it had been
prescribed.
Three patients talked about wanting to know how long
they would have to take their medicines for, which sug-
gested concern about the potential to be taking medi-
cines indefinitely, although there was no suggestion that
this had affected their decision to continue taking them.
For example, one patient said “It’s waiting just how long
I’ve got to take them, is it going to be forever and a
day?”, whilst another said that he had wanted to know:
“…for how long you’re going to have to take them. I
accept that most of them I’ll be taking for the rest of
my life…but I was told maybe six to twelve months,
this is the basic time for drugs. So we’ll have to see
what happens after that.” (R13: male)
Two patients talked about being concerned about
differences in the information between written sources
of information or differences of opinion between health
professionals about their medicines. One said that he had
read a book about CHD that his GP had recommended
and said that this had caused “an element of uncertainty”
over why certain medicines-related aspects differed from
his own circumstances. He said that he had asked his GP
about these but it seemed that this had not fully an-
swered all of his questions, such as that “it says nobody
should really be on above seventy-five [milligrams] of as-
pirin, well I’m on double that”. He knew that this was be-
cause it was what his consultant “recommends”, but this
still did not explain why his consultant’s view differed
from what he had read in the book. He also said “it wor-
ried me taking eight different types of tablets” because “it
does say in the book that the most tablets patients would
normally be on is three or four tablets a day”. This
seemed to have worried him because it did not appear to
be consistent with having had a “mild heart attack”, as he
said he had been told when he had been in hospital.
Nevertheless, he pointed out that he was continuing to
take these medicines. The other patient said that she was
“not quite sure” why there seemed to be a difference
of opinion between her GP and her consultant about
whether she should be on a beta-blocker or an ACE in-
hibitor and said that although she was continuing to take
the beta-blocker, at her next “check up” with her consult-
ant she intended to ask about whether she should be pre-
scribed an ACE inhibitor.
One patient said that what he had particularly wanted
to know was why his dose of warfarin had been in-
creased when he last went to have his “blood checked”,
since this had not been explained to him at the time. He
said that he wanted information about “why you’ve got
to reduce it, why you’ve got to increase it” so that he
could understand why:
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anything they can tell you, maybe I’m doing something
wrong…maybe there’s something I can do myself to
help my blood stay at that sort of level…” (R1: male)
It seemed that the main reason why he wanted to know
this was because he had been worried that his blood not
being “at that sort of level” meant that there was something
wrong that might lead to another heart attack. He reported
that he had been taking this higher dose, and still hoped
that he would be given an explanation at some point.
In the follow-up interviews the same issues in applying
the ‘medicines-resistance’ model were encountered
(i.e. whether patients accepted their medicines despite
concerns not being resolved, and whether they modified
their regimen). The patients who were concerned about
side effects in the initial interview continued to have
concerns, but all of the patients said that they were
continuing to take their medicines as prescribed. For
example, one of these patients explained that:
“When I changed the tablets over from ramipril to
losartan, oh it took me a long time to get used to them
and I didn’t feel as well on them as I did on ramipril.
I couldn’t really explain it, not very well in myself. It
was a question of energy…[ramipril] is tried and true
and I think it works and I don’t know about losartan
whether it does or not. I don’t cough as much but was
it as effective as the ramipril?” (R2: female)
Her description of this dilemma suggested that she
had not really accepted the alternative choice of medi-
cine, but in continuing to take it as prescribed, she was
not ‘resistant’ to it either.
The patient who was concerned about getting “discom-
fort” in his chest had eventually been told that the dis-
comfort was “all to do with indigestion” rather than
being related to his heart. He explained that subsequently
other “tablets started that way” and he had not experi-
enced the “discomfort” since. This seemed to have caused
him to question whether certain heart-related medicines
that had been started or had doses increased to deal with
this “discomfort” were necessary because they had not re-
lieved his “discomfort”. He said that he had “badgered”
his GP to reduce these medicines because he did “want
to alter them but I only want to do it through my GP so
he knows what’s happening”, rather than just deciding
not to take them. The principal difficulty in applying the
‘medicines-resistance’ model here was that on the one
hand he accepted and took his medicines as prescribed,
but on the other hand he had a clear interest in his medi-
cines regimen being modified to avoid side effects. How-
ever, he was not modifying (and hence was not showing
‘resistance’ to) his medicines per se, neither was hemodifying his regimen without his doctor’s knowledge.
The issues raised by these findings and the implications
for the medicines-resistance model are now discussed
in more detail.
Discussion
These findings suggest that, since all the of patients
reported taking their medicines as prescribed, it is diffi-
cult to place them into the category of either ‘complete
rejecter’ or ‘active modifier’, and in practically apply-
ing the ‘medicines-resistance’ model the distinctions of
passive/active and accepter/modifier became problem-
atic, as did the definitions of ‘accepter’ and ‘resistance’. It
is possible that these issues are more apparent in the con-
text of CHD patients, since no papers concerning CHD
were included in Pound et al’s meta-ethnography [6],
which may suggest greater disease specificity than the
model currently allows for. We accept that the results of
this study are based on the participants’ expressed views
and so may not necessarily have wider applicability and
that there is the possibility of a social desirability effect,
where the patients responded in a way dependent on who
they perceived the interviewer to be. However, it is also
possible that the ‘medicines-resistance’ model of medicine-
taking, as it currently stands, does not adequately ac-
count for the complexity of medicine-taking behaviour
as characterised through the experiences of CR patients.
The problem with determining whether some patients
had ‘passively accepted’ their medicines was that al-
though they had apparently deferred to their doctor’s
judgement, they were also found to have undergone a
process of almost continuous self-evaluation of their
medicines. This was so, even if only in terms of checking
that they were ‘feeling alright’. Since this is suggestive of
an active process, categorising them as having accepted
their medicines ‘without question’ becomes problematic.
Furthermore, choosing to defer to the doctor’s judge-
ment is arguably more an active process of acceptance
than passive. The issue with the accepter/modifier dis-
tinction was that some patients sought medical advice
because of intolerable side effects but continued to take
the medicines thought to be responsible unless the doc-
tor prescribed an alternative. It remains unclear as to
whether ‘active acceptance’ can reasonably include seek-
ing medical intervention with the hope of getting a par-
ticular medicine stopped or changed, but since they
were prepared to take alternatives, categorising them as
‘resistant’ is also problematic. However, it could be
argued that this is more suggestive of ‘active modifica-
tion’ than ‘active acceptance’, but if so it would perhaps
be better categorised as ‘modification by proxy’, since the
decision to modify was made by the doctor after a prob-
lem had been identified by the patient. The point made
in the ‘medicines-resistance’ model (Figure 1) that ‘some
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may affect medicine-taking’ does not clarify these issues, as
the model only appears to show this leading to rejection of
medicines. Britten argues that the profiles of ‘accepter’,
‘modifier’ and ‘rejecter’ do not have to be considered as
being static, since people may change their approach to
medicines [17], but this study highlights the more fun-
damental problem in determining which category a pa-
tient may fit at any given point.
Determining whether the ‘medicines-resistance’ model
could be applied to the patients in this study was also
hindered by the lack of clear definitions of what might
constitute ‘resistance’ and what constitutes an ‘accepter’.
The model (Figure 1) indicates that ‘resistance’ is shown
by those who completely reject or modify their pre-
scribed medicines regimen, whereas Pound et al. later
referred to ‘resistance’ in the rather broader context of a
‘considerable reluctance to take medicine and a prefer-
ence to take as little as possible’ [6]. The findings of this
study indicated that over half of the patients expressed
worries and concerns about taking medicines, which in
this broader context could perhaps be viewed as ‘resist-
ance’ even though all patients reported taking their
medicines as prescribed (although we accept that there
may be differences between their accounts and actual
practice). The problem with the notion of ‘acceptance’
concerns the extent to which patients could be consid-
ered to have accepted their medicines in the absence of
resolution of their worries and concerns, despite self-
evaluation. Morgan considered this to be ‘problematic ad-
herence’ in her study of hypertensive patients (included in
Pound et al’s meta-ethnography) and explained this by
saying that although patients took their medicines, they
were not ‘reconciled’ to using them long-term, worried
about the potential for long-term adverse effects and
disliked ‘feeling addicted’ to them [18]. This implies that
patients had not accepted their medicines any more than
patients had in the present study, unless a very broad
understanding of the term acceptance is employed.
Despite these apparent limitations of the ‘medicines-
resistance’ model, the findings from the study presented
here do support Pound et al’s work [6], insofar as that
most patients expressed concerns about taking medi-
cines, especially concerning the potential for them to
cause harm. Subsequently, patients tended to take a par-
ticular interest in medicines information about these is-
sues. This has been reported by other studies of CR
patients, and CHD patients who may not have attended
a CR programme [19-21]. It has also been reported in
the literature more generally [22]. What perhaps many
patients in this study were showing was a sense of dis-
content, or disquiet, about their medicines, for a variety
of reasons but particularly about side effects. This was
coupled with a keen desire to avoid further CHD-relatedevents, awareness of the subsequent need to take regular
medicines and a strong sense of acceptance towards their
doctor’s prescribing expertise. In some instances, as has
been discussed, their disquiet prompted patients to seek
medical advice with the hope of the medicine being
stopped or an alternative prescribed. This perhaps goes
beyond Morgan’s concept of ‘problematic adherence’ [18],
although it should be pointed out that patients reported
continuing to take the medicines thought to be causing
their disquiet, unless prescribed an alternative.
The problems inherent in practically applying the
‘medicines-resistance’ model appear to arise when adher-
ence is taken into account, since features of ‘resistance’ to
medicines (i.e. what we term disquiet) may be seen in
patients who because they appear to be adherent would
not otherwise be categorised as ‘resistant’, as has been
shown in this study. Norreslet et al described medicines
being viewed as a ‘necessary evil’ amongst patients with
atopic dermatitis, who appeared to have gone through pe-
riods of what could be viewed as ‘resistance’ to certain
medicines (e.g. topical corticosteroids) because of their side
effects [23]. Nevertheless, patients eventually felt that they
had no choice but to use these medicines because there
were no other effective treatments. The point here is not
that they had changed from being ‘resistant’ to being ‘active
accepters’, in line with Britten’s point about the ‘medicines
resistance’ model profiles not being static [17], but that
their considerable disquiet continued, and that this was a
central feature of their accounts of using medicines. In
contrast, the CR patients in the present study did have ef-
fective alternatives available, which reduced the ‘evil’, whilst
preserving the ‘necessary’. McCoy has similarly written
about the work involved for patients in ‘doing adherence’
to antiretroviral medicines for HIV and described features
that could be considered as ‘resistance’ [24]. Here again
these features may be better understood as disquiet, since
patients were to all intents and purpose adherent, whilst
doing the work of successfully accommodating medicine-
taking into their everyday lives. In terms of the implications
for practice, this suggests that a more fruitful approach
would be to dissociate disquiet about medicines from
non-adherence to medicines and where patients do require
support with adherence, the UK National Institute of
Health and Clinical Excellence guidance, amongst
other resources, offers a practical approach [25]. When
viewed in this way the notion of ‘medicines-resistance’
may become less relevant and the focus can shift onto
helping patients to resolve their disquiet, where possible,
without this necessarily being viewed in terms of the
potential effect on non-adherence.
Conclusions
In this paper we have argued that the practical applica-
tion of the ‘medicines resistance’ model of medicine-
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The active/passive and accepter/modifier distinctions may
not allow for clear determination of which profile a patient
may fit at any given point, and that the definitions of ‘ac-
cepter’ and ‘resistance’ may be insufficiently discerning to
categorise patients’ use of medicines in practice. We have
pointed out that these problems arise when the issue of ad-
herence is taken into account, since the ‘medicines resist-
ance’ model does not consider disquiet about medicines in
isolation. Subsequently, since disquiet may well be a feature
of both adherence and non-adherence to medicines, dis-
sociation of disquiet from adherence may allow for a focus
on helping patients to resolve their disquiet, if possible,
without this necessarily having to be viewed in terms of its
potential effect on adherence. As such, we suggest that a
more fruitful approach may be to focus more on patients’
disquiet about medicines and less on whether or not they
are ‘resistant’.
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